TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic in acute ischemic stroke (AIS) and TTP

TGD001 is being developed to offer patients with clotting disorders a faster, safer and more effective treatment than today’s...

Financing co-led by Johnson & Johnson Innovation – JJDC, Inc., Forbion and Novartis Venture Fund Lead first-in-class product...

Amsterdam, Netherlands – 13 August 2024 – Pitchbook has recently awarded Curie Capital with a 5th place among Dutch Venture...

   Learnings will be used in the clinical development programs of NET-targeting therapies such as Citryll’s lead...

• V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders...

OSS, the Netherlands, 13-02-2024 — Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat...